GlassScriptPhysician profile
Amanda Huang
NPI 1942715487
$3,138.00
in general payments reported to CMS, 2019-2025
21 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $60.70 · 2023: $196 · 2024: $1,825 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,056 · Education: $21.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.58 |
| Education | $21.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $604.44 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Inspire Medical Systems, INC. | $493.53 | 2024-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $400.67 | 2022-2025 | |
| Genzyme Corporation | $338.86 | 2023-2025 | |
| Glaxosmithkline, LLC. | $280.50 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Avadel Cns Pharmaceuticals, LLC | $206.90 | 2024-2025 | Lumryz |
| Harmony Biosciences LLC | $193.25 | 2022-2025 | |
| Amgen INC. | $139.58 | 2023-2025 | Tezspire |
| Axsome Therapeutics, INC. | $89.77 | 2023-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $85.31 | 2024 | Dupixent |
| Insmed, INC. | $62.83 | 2024-2025 | Arikayce |
| Idorsia Pharmaceuticals US INC | $45.71 | 2024 | Quviviq |
| Abbvie INC. | $33.58 | 2023 | |
| Viatris Specialty LLC | $28.94 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $25.99 | 2024 | Glassia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $24.63 | 2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.78 | 2025 | Jascayd |
| Arbor Pharmaceuticals, INC. | $17.64 | 2022 | |
| Merck Sharp & Dohme LLC | $17.63 | 2024 | Winrevair |
| Mylan Specialty L.P. | $14.69 | 2024 | Yupelri |
| Verona Pharma, INC. | $13.77 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.